Roche has signed up for access to Vividion Therapeutics' proteomics screening platform and proprietary small molecule library to target E3 ligases and a range of oncology and immunology therapeutic targets.
Roche has signed an exclusive worldwide option and licence agreement with US-based biotechnology firm Vividion Therapeutics to discover and develop small molecules for various therapeutic targets.